Associated Papers
Current Progress on Equilibrative Nucleoside Transporter Function and Inhibitor Design.
Rehan S et al.
Slas Discovery : Advancing Life Sciences R & D, 2019
Pharmacogenetic determinants of mercaptopurine disposition in children with acute lymphoblastic leukemia.
Adam de Beaumais T et al.
European Journal of Clinical Pharmacology, 2012
Pharmacogenetics influence treatment efficacy in childhood acute lymphoblastic leukemia.
Davidsen ML et al.
Journal of Pediatric Hematology/oncology, 2008
Residues Met89 and Ser160 in the human equilibrative nucleoside transporter 1 affect its affinity for adenosine, guanosine, S6-(4-nitrobenzyl)-mercaptopurine riboside, and dipyridamole.
Endres CJ et al.
Molecular Pharmacology, 2005
Select a paper to view details